Statins in patients with chronic kidney disease – an attempt at recommendations

Banach, Maciej

doi:10.1185/03007995.2013.833502

Cited by 8 publications

(9 citation statements)

References 32 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although reports from large clinical trials concerning the treatment of CKD patients with statins are sparse, available data suggest that statins are effective and safe for secondary prevention of CV events in individuals with mild CKD [14,60]. According to the meta-analysis by Strippoli et al [1], statin administration was associated with a considerable reduction in the risk of non-fatal CV events [by 20 %, relative risk (RR) 0.78, 0.73-0.84] in comparison with placebo.…”

Section: Effects Of Statins On the Occurrence Of CV Eventsmentioning

confidence: 99%

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

“…According to the aforementioned guidelines, statins use should be considered in CKD patients due to their ability to retard kidney function loss and to protect against the development of dialysis-dependent ESRD (IIa/C level of recommendation/evidence) [60,70]. The use of statins in patients with moderate to severe CKD should be considered in order to achieve LDL-C 570 mg/dL (1.8 mmol/L) (IIa/C level of recommendation/ evidence) [60,70]. In the global recommendations for the management of dyslipidemia issued by the International Atherosclerosis Society (IAS), there appears a suggestion that in CKD patients the optimal range of LDL-C should be <100 mg/dL (2.6 mmol/L) [60,71].…”

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

“…The use of statins in patients with moderate to severe CKD should be considered in order to achieve LDL-C 570 mg/dL (1.8 mmol/L) (IIa/C level of recommendation/ evidence) [60,70]. In the global recommendations for the management of dyslipidemia issued by the International Atherosclerosis Society (IAS), there appears a suggestion that in CKD patients the optimal range of LDL-C should be <100 mg/dL (2.6 mmol/L) [60,71]. Also the recent 2012 update of the Canadian CV Society guidelines recommends the use of statins in CKD patients in order to lower lipid levels and as a prevention of CV disease [72].…”

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

“…Atherosclerosis Society (EAS) 2011 guidelines indicate that CKD patients should be treated as individuals at very high CV risk and thus they should have all risk factors adequately managed [60,70]. According to the aforementioned guidelines, statins use should be considered in CKD patients due to their ability to retard kidney function loss and to protect against the development of dialysis-dependent ESRD (IIa/C level of recommendation/evidence) [60,70].…”

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

See 4 more Smart Citations

Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge

et al. 2015

Self Cite

View full text Add to dashboard Cite

Meta-analyses results suggest that statins are associated with lipid lowering, cardiovascular and anti-proteinuric benefits in CKD patients. However, their effects on overall and cardiovascular mortality are much less obvious. Bearing in mind the advantageous effects and low risk of adverse effects, it seems that mild renal impairment should not exclude these patients from receiving a statin. However, because CKD patients in stages III-V are underrepresented in clinical trials, administration of statins to these patients who have not yet had a vascular event remains controversial.

show abstract

Section: Effects Of Statins On the Occurrence Of CV Eventsmentioning

confidence: 99%

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

Section: Current European Society Of Cardiology (Esc)/europeanmentioning

confidence: 99%

See 3 more Smart Citations

Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Lipid, blood pressure and kidney update 2013

et al. 2014

Self Cite

View full text Add to dashboard Cite

The year 2013 proved to be very exciting as far as landmark trials and new guidelines in the field of lipid disorders, blood pressure and kidney diseases. Among these are the International Atherosclerosis Society Global Recommendations for the Management of Dyslipidemia, European Society of Cardiology (ESC)/European Society of Hypertension Guidelines for the Management of Arterial Hypertension, American Diabetes Association Clinical Practice Recommendations, the Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease (CKD) Patients, the American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, the Joint National Committee Expert Panel (JNC 8) Evidence-Based Guideline for the Management of High Blood Pressure in Adults, the American Society of Hypertension/International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Community, the American College of Physicians Clinical Practice Guideline on Screening, Monitoring, and Treatment of Stage 1–3 CKD and many important trials presented among others during the ESC Annual Congress in Amsterdam and the American Society of Nephrology Annual Meeting—Kidney Week in Atlanta, GA. The paper is an attempt to summarize the most important events and reports in the mentioned areas in the passing year.

show abstract